Extract
Adequate drug exposure is important to ensure tuberculosis (TB) treatment efficacy and to avoid acquired drug resistance. Although low drug exposure has been reported for most anti-TB drugs, data on drug exposure in relation to minimum inhibitory concentration (MIC) are scarce [1, 2]. A fluoroquinolone is a cornerstone in the treatment of multidrug-resistant (MDR)-TB, which results when Mycobacterium tuberculosis is resistant to rifampicin and isoniazid. The activity of fluoroquinolones is best described by the area under the concentration–time curve based on free drug in relation to MIC (fAUC/MIC) [3, 4].
Abstract
This study found target attainment of 0–55% for patients with multidrug-resistant TB using currently recommended doses of moxifloxacin (55%) and levofloxacin (0%), meaning increased doses should be considered to ensure efficacy, if safety can be assured https://bit.ly/3juED6S
Acknowledgements
We thank the patients for their participation and Brian Davies for language revision.
Footnotes
This study is registered at www.ClinicalTrials.gov with identifier number NCT02816931. Data may be shared upon request.
Conflict of interest: L. Davies Forsman has nothing to disclose.
Conflict of interest: K. Niward has nothing to disclose.
Conflict of interest: J. Kuhlin has nothing to disclose.
Conflict of interest: X. Zheng has nothing to disclose.
Conflict of interest: R. Zheng has nothing to disclose.
Conflict of interest: R. Ke has nothing to disclose.
Conflict of interest: C. Hong has nothing to disclose.
Conflict of interest: J. Wengren has nothing to disclose.
Conflict of interest: J. Paues has nothing to disclose.
Conflict of interest: U.S.H. Simonsson has nothing to disclose.
Conflict of interest: E. Eliasson has nothing to disclose.
Conflict of interest: S. Hoffner has nothing to disclose.
Conflict of interest: B. Xu has nothing to disclose.
Conflict of interest: J-W. Alffenaar has nothing to disclose.
Conflict of interest: T. Schön has nothing to disclose.
Conflict of interest: Y. Hu has nothing to disclose.
Conflict of interest: J. Bruchfeld has nothing to disclose.
Support statement: This work was supported by the Swedish Heart Lung Foundation (grant number 20150508), the Swedish National Research Council (grant numbers 540-2013-8797, 2016-02043 (T. Schön), 2019-05901 (L. Davies Forsman)), the National Research Foundation of China (grant number 81361138019), SLL grant 2018-1256 (L. Davies Forsman) and 2019-0536 (E. Eliasson). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received July 13, 2020.
- Accepted October 20, 2020.
- Copyright ©ERS 2021